Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 330M |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
18 |
| Average PDX Generation Time (days +/- SEM) | 90 ± 9 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 330M |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 330M | PIK3R2 | 0.723 | 3.302 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | KEAP1 | -0.975 | 1.017 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | KEAP1 | -0.740 | 1.197 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | TP53 | -0.802 | 1.147 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | CDH1 | -0.795 | 1.153 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | PALB2 | -0.806 | 1.144 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | CDKN1B | -1.511 | 0.702 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | KMT2C | -1.395 | 0.761 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | AR | 4.355 | 20.468 | Gain-High | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | SETDB1 | 1.798 | 6.957 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | EZH2 | 0.774 | 3.420 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | EZH2 | 0.884 | 3.691 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | BRAF | 0.735 | 3.328 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | MET | 0.840 | 3.581 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | PIK3CA | 0.834 | 3.564 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | PIK3CB | 0.608 | 3.049 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 330M | PIK3CB | 0.798 | 3.477 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 330M |
|---|---|
| Sample Site | Liver |
| Sample source | Biopsy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
Patient Information
| Patient Number | 330 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 330M |
| Patient Age (binned in 5 year age groups) | 55-59 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 330M | TP53 | 200 | 0.99 | Splice acceptor variant | . | . | 24.8 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | RB1 | 197 | 0.99 | Stop gained | '20/27 | . | 43 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | MAG | 377 | 0.66 | Missense variant | '4/11 | 4.08E-06 | 25.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | VPS13B | 316 | 0.6 | Stop gained | '20/62 | . | 39 | Pathogenic/likely pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | RET | 499 | 0.47 | Missense variant | '11/20 | . | 22.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | MEN1 | 230 | 0.4 | Missense variant | '2/10 | . | 22.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | LTBP4 | 601 | 0.32 | Missense variant | '34/34 | 0.0003721 | 27.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | MAST4 | 252 | 0.29 | Splice donor variant | . | . | 34 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 330M | XIRP2 | 428 | 0.29 | Missense variant | '9/11 | . | 25.6 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table